← Aditya Birla Sun Life Mutual Fund

ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND

Equity Data as of Oct 2026 Comparing Sep 2026 → Oct 2026
Share: WhatsApp X
Stocks Held
40
Oct 2026
Equity Holdings
₹1,081.56 Cr
Equity only, excl. debt & cash
AAUM
₹1,063.05 Cr
Jul-Sep 2026 · Direct + Regular
Top 5 Weight
35.4%
Moderate
Top 10 Weight
54.6%
Moderate
Changes
39
2 new · 1 exits
Top Sector
Pharmaceuticals & Biotechnology
76.4% of portfolio
Launch Date
20 Jun 2019
7 years old

AAUM (Average Assets Under Management) of ₹1,063.05 Cr for Jul-Sep 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.

📋 What Happened This Month ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND made 2 new additions and exited 1 stock this month. The biggest new buy was Eris Lifesciences Limited (Pharmaceuticals & Biotechnology) at 1.59% weight. Shilpa Medicare Ltd was the biggest exit (Pharmaceuticals & Biotechnology), which was held at 1.43%. Among existing holdings, Cipla Limited saw the biggest increase — now at 7.10% of the portfolio. Torrent Pharmaceuticals Limited was trimmed the most, now at 8.83%. Torrent Pharmaceuticals Limited remains the top holding with Pharmaceuticals & Biotechnology the dominant sector at 76.4%. ↓ Scroll down for full holdings, sector allocation and month-on-month changes in detail.
Sector Shift Industry allocation month-over-month
Aug 2026 → Sep 2026
Sector Prev Curr ▼ Delta
Pharmaceuticals & Biotechnology 73.3% 74.9% ▲ +1.7%
Healthcare Services 21.6% 21.6% ● +0.0%
Insurance 0.8% 0.7% ● -0.1%
Chemicals & Petrochemicals 0.8% 0.7% ● -0.1%
Sep 2026 → Oct 2026
Sector Prev Curr ▼ Delta
Pharmaceuticals & Biotechnology 74.9% 76.4% ▲ +1.5%
Healthcare Services 21.6% 21.7% ▲ +0.1%
Insurance 0.7% 0.7% ● 0.0%
Chemicals & Petrochemicals 0.7% 0.6% ▼ -0.1%
🟢
Biggest New Buy
Eris Lifesciences Limited
1.59% weight · Pharmaceuticals & Biotechnology
🔴
Biggest Exit
Shilpa Medicare Ltd
1.43% was held · Pharmaceuticals & Biotechnology
↑
Biggest Add
Cipla Limited
+0.72% · now 7.10%
↓
Biggest Trim
Torrent Pharmaceuticals Limited
-0.45% · now 8.83%
🤝 Other funds also bought this month
Onesource Specialty Pharma Limited 16 funds
Onesource Specialty Pharma Limited
WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth
Aditya Birla Sun Life Value Fund - Growth - Direct Plan
LIC MF Manufacturing Fund-Direct Plan-Growth + more
Eris Lifesciences Limited 6 funds
Eris Lifesciences Limited
Franklin India Retirement Fund - Direct - Growth
Mirae Asset Aggressive Hybrid Fund
Angel One Nifty Total Market Index Fund + more
👋 Other funds also exited
Shilpa Medicare Ltd 2 funds
Shilpa Medicare Ltd
WhiteOak Capital Special Opportunities Fund - Direct Growth
Bandhan Nifty Total Market Index Fund

What Changed in the Portfolio This Month?

Comparing Sep 2026 → Oct 2026

Sep 2026 → Oct 2026
🟢 2 New Entries 🔴 1 Exit ↑ 14 Increased ↓ 22 Decreased
#StockSectorWeight (Oct 2026)
1
Eris Lifesciences Limited
₹17.35 Cr
Pharmaceuticals & Biotechnology 1.59%
2
Onesource Specialty Pharma Limited
₹9.38 Cr
Pharmaceuticals & Biotechnology 0.86%
#StockSectorLast Weight (Sep 2026)
1
Shilpa Medicare Ltd
₹15.39 Cr
Pharmaceuticals & Biotechnology 1.43%
#StockSectorSep 2026Oct 2026Change
1
Cipla Limited
₹77.28 Cr
Pharmaceuticals & Biotechnology 6.38% 7.10% +0.72%
2
Dr. Reddy's Laboratories Limited
₹20.14 Cr
Pharmaceuticals & Biotechnology 1.13% 1.85% +0.72%
3
Dr. Lal Path Labs Limited
₹42.43 Cr
Healthcare Services 3.51% 3.90% +0.39%
4
Biocon Limited
₹19.42 Cr
Pharmaceuticals & Biotechnology 1.45% 1.79% +0.34%
5
Piramal Pharma Limited
₹16.68 Cr
Pharmaceuticals & Biotechnology 1.22% 1.53% +0.31%
6
Apollo Hospitals Enterprise Limited
₹71.75 Cr
Healthcare Services 6.44% 6.60% +0.16%
7
Gland Pharma Limited
₹31.12 Cr
Pharmaceuticals & Biotechnology 2.70% 2.86% +0.16%
8
Divi's Laboratories Limited
₹25.43 Cr
Pharmaceuticals & Biotechnology 2.24% 2.34% +0.10%
9
Syngene International Limited
₹7.61 Cr
Healthcare Services 0.64% 0.70% +0.06%
10
Metropolis Healthcare Limited
₹16.73 Cr
Healthcare Services 1.48% 1.54% +0.06%
#StockSectorSep 2026Oct 2026Change
1
Torrent Pharmaceuticals Limited
₹96.08 Cr
Pharmaceuticals & Biotechnology 9.28% 8.83% -0.45%
2
GlaxoSmithKline Pharmaceuticals Limited
₹5.71 Cr
Pharmaceuticals & Biotechnology 0.83% 0.53% -0.30%
3
Thyrocare Technologies Limited
₹16.18 Cr
Healthcare Services 1.76% 1.49% -0.27%
4
Sun Pharmaceutical Industries Limited
₹90.81 Cr
Pharmaceuticals & Biotechnology 8.61% 8.35% -0.26%
5
Abbott India Limited
₹33.15 Cr
Pharmaceuticals & Biotechnology 3.26% 3.05% -0.21%
6
Ajanta Pharma Limited
₹45.37 Cr
Pharmaceuticals & Biotechnology 4.35% 4.17% -0.18%
7
Emcure Pharmaceuticals Limited
₹33.27 Cr
Pharmaceuticals & Biotechnology 3.21% 3.06% -0.15%
8
Suraksha Diagnostic Ltd
₹10.59 Cr
Healthcare Services 1.10% 0.97% -0.13%
9
Vinati Organics Limited
₹6.35 Cr
Chemicals & Petrochemicals 0.69% 0.58% -0.11%
10
SANOFI CONSUMER HEALTHCARE
₹10.86 Cr
Pharmaceuticals & Biotechnology 1.11% 1.00% -0.11%

What Stocks Does This Fund Hold?

40 stocks — Oct 2026

# Stock Sector Cap Weight & Value
1
₹96.08 Cr
Pharmaceuticals & Biotechnology
8.83%
2
₹90.81 Cr
Pharmaceuticals & Biotechnology
8.35%
3
₹77.28 Cr
Pharmaceuticals & Biotechnology
7.10%
4
₹71.75 Cr
Healthcare Services
6.60%
5
₹49.41 Cr
Pharmaceuticals & Biotechnology
4.54%
6
₹48.97 Cr
Pharmaceuticals & Biotechnology
4.50%
7
₹45.37 Cr
Pharmaceuticals & Biotechnology
4.17%
8
₹42.43 Cr
Healthcare Services
3.90%
9
₹38.78 Cr
Pharmaceuticals & Biotechnology
3.56%
10
₹33.27 Cr
Pharmaceuticals & Biotechnology
3.06%
🏆 Top stocks held by Equity funds
See which stocks all active Equity fund managers are buying — ranked by total value invested
→
🏦 Aditya Birla Sun Life Mutual Fund — Portfolio & Holdings
See all funds managed by Aditya Birla Sun Life Mutual Fund — conviction stocks, monthly entries & exits
→

Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.

Found a discrepancy or have feedback? Contact Us — we read every message personally.